DCM
CMPX icon

DAFNA Capital Management’s Compass Therapeutics CMPX Stock Holding History

DAFNA Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-946,661
Closed -$3.31M – 80
2025
Q3 		$3.31M Buy
946,661
+420,001
+80% +$1.33M 0.82% 32
2025
Q2 		$1.37M Buy
+526,660
New +$1.09M 0.38% 49
2025
Q1 		– Sell
-158,394
Closed -$230K – 86
2024
Q4 		$230K Buy
158,394
+41,512
+36% +$68.9K 0.06% 80
2024
Q3 		$215K Hold
116,882
– – 0.05% 81
2024
Q2 		$117K Hold
116,882
– – 0.03% 83
2024
Q1 		$231K Hold
116,882
– – 0.05% 70
2023
Q4 		$182K Hold
116,882
– – 0.04% 72
2023
Q3 		$230K Hold
116,882
– – 0.07% 69
2023
Q2 		$372K Hold
116,882
– – 0.1% 63
2023
Q1 		$382K Sell
116,882
-485,169
-81% -$1.9M 0.11% 66
2022
Q4 		$3.03M Buy
602,051
+413,957
+220% +$1.65M 0.85% 35
2022
Q3 		$429K Sell
188,094
-10,000
-5% -$27.7K 0.12% 76
2022
Q2 		$525K Buy
198,094
+2,003
+1% +$4.35K 0.14% 74
2022
Q1 		$269K Hold
196,091
– – 0.07% 88
2021
Q4 		$622K Buy
+196,091
New +$650K 0.16% 77

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DAFNA Capital Management's CMPX Position: Q4 2025 in Review

DAFNA Capital Management sold out of Compass Therapeutics (CMPX) in Q4 2025, closing a stake of 946,661 shares — an estimated $3.31M sold.

DAFNA Capital Management first reported a position in CMPX in Q4 2021 and held it in 15 quarters. The position peaked at $3.31M in Q3 2025. 173 funds tracked by Wall St. Rank hold CMPX as of Q4 2025.

  • DAFNA Capital Management reported no remaining Compass Therapeutics position as of Q4 2025 after selling out during the quarter.
  • DAFNA Capital Management sold 946,661 Compass Therapeutics shares in Q4 2025, an estimated $3.31M.
  • DAFNA Capital Management first reported a position in Compass Therapeutics in Q4 2021 and held it in 15 quarters.
  • DAFNA Capital Management's Compass Therapeutics position peaked at $3.31M in Q3 2025.
  • 173 funds tracked by Wall St. Rank held Compass Therapeutics as of Q4 2025.

Based on DAFNA Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.